



Veracyte, Inc.  
Investor Relations Department  
6000 Shoreline Court  
Suite 300  
South San Francisco, CA 94080  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: VCYT

Last Trade:	9.04
Trade Time:	4:00 PM ET Oct 16, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	5.82 - 9.71
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company's products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary. [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Oct 13, 2017*

[Veracyte Chairman and CEO Bonnie Anderson Receives Prestigious Innovation Award at Biomedical Engineering Society Annual Meeting](#)

*Oct 5, 2017*

[Veracyte Announces Data From Five Studies Validating the Next-Generation Afirma Genomic Sequencing Classifier to Be Presented at ATA 2017 Annual Meeting](#)

*Sep 25, 2017*

[Veracyte Announces Release of 2018 Preliminary Reimbursement Rate for Afirma Genomic Classifier Under PAMA](#)

*Sep 19, 2017*

[Awareness Campaign Takes Lung Cancer Risk Head-On, Asking North Carolinians To Screen Together](#)

*Sep 19, 2017*

[Veracyte Launches Campaign to Save Lives through Early Screening for Lung Cancer](#)

## Financials [\[ View all \]](#)

[First Quarter Financial Results](#)

*Mar 1, 2017*

[Annual Report \(10-K\)](#)

*Apr 21, 2017*

[Proxy Statement \(DEF 14A\)](#)

*Jul 31, 2017*

[Quarterly Report \(10-Q\)](#)

*May 3, 2017*

[Quarterly Report \(10-Q\)](#)

*Nov 3, 2016*

[Quarterly Report \(10-Q\)](#)